Drugs / BMS-986458
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06090539 | Dec 2023 → Oct 2027 expected | non-Hodgkin lymphoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-12-01 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio bms.com ↗
Updated results for BMS-986458, a first-in-class bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6, demonstrate encouraging efficacy and tolerability in R/R non-Hodgkin lymphoma (NHL) (Oral presentation #480) |
| 2025-06-12 | Bristol-Myers Squibb | Results Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 bms.com ↗ |
| 2024-11-19 | Bristol-Myers Squibb | Results Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms bms.com ↗
Preclinical results for potential first-in-class ligand-directed degrader of BCL6 BMS-986458 demonstrating anti-tumor efficacy in B-cell non-Hodgkin lymphoma (NHL) |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-01 | Bristol-Myers Squibb | Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio bms.com ↗ |
| 2025-06-12 | Bristol-Myers Squibb | Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 bms.com ↗ |
| 2024-11-19 | Bristol-Myers Squibb | Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms bms.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986458 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06090539 ↗ |
| Target | BCL6 | “BMS-986458 induces rapid cereblon-dependent BCL6 degradation” PMID 41670385 ↗ Feb 2026 |